Intellectual Property

The folks at the U.S. Patent and Trademark Office are trying to remedy the slow process of patent processing by erasing redundancies and increasing efficiency through various methods, all discussed — but not solved — at a recent roundtable held at USPTO headquarters in Alexandria, Va.

A patent case winding its way through U.S. District Court has the potential to hinder biotechnology R&D if the judge hearing the case rules in favor of the plaintiffs, led by the American Civil Liberties Union.

The purpose of this survey was to examine the extent and importance of technology transfer and licensing activity involving biotechnology companies.

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

Today, the biotechnology industry is enjoying more success and influence than ever before. Our industry’s innovations continue to improve the lives of people worldwide, and the advancement of these innovations is supported by the work of BIO.

Economists have long recognized that the development and spread of economic innovations are the most powerful factors affecting how fast the U.S. economy grows and how much the incomes of most Americans will rise.

Certain groups are calling for serious overhaul of the nation‟s patent system.

October 14 2014
The Biotechnology Industry Organization (BIO) appreciates this fifth opportunity to formally respond to the Colombian Ministry of Health’s Draft Decree on Regulatory Requirements for the Registry of Medicines of Biological Origin.
April 2 2014
BIO joins coalition letter to Chairman Patrick Leahy and Ranking Member Chuck Grassley expressing serious concerns with the direction of patent legislation.
February 25 2014
BIO appreciates the opportunity to participate in the Special 301 process and is hopeful that our contribution will assist the United States Trade Representative’s (USTR) efforts in preserving strong intellectual property protections for United States’ companies internationally. BIO appreciates the opportunity to comment on 2014 Special 301 Review: Identification of Countries Under Section 182 of the Trade Act of 1974: Request for Public Comment and Announcement of Public Hearing.
February 24 2014
Lila Feisee, Vice President of International Affairs testified on behalf of BIO and its 1100 members who innovate in the healthcare, agriculture, industrial, and environmental sectors. 
November 20 2013
BIO welcomes the opportunity to provide the views of its members on facilitating access to genetic resources and traditional knowledge and the sharing of benefits from their use...
May 21 2014
BIO applauds Chairman Leahy’s decision to remove the controversial patent bill from the Senate Judiciary Committee’s agenda until greater stakeholder consensus can be achieved.
February 26 2014
Transparent communication important for Patients and Physicians
December 4 2013
BIO and the American Seed Trade Association (ASTA) announced today that the Data Use and Compensation Agreement (DUCA) is open for signature. 
December 3 2013
BIO issued the following statement regarding the Innovation Act (H.R. 3309), as reported by the House Judiciary Committee.
June 13 2013
The SCOTUS decision represents a departure from judicial and PTO precedent supporting patentability of DNA molecules. The decision could create business uncertainty for a range of inventions.